Cullinan Therapeutics Inc (NAS:CGEM)
$ 23.49 0.71 (3.12%) Market Cap: 1.35 Bil Enterprise Value: 883.64 Mil PE Ratio: 0 PB Ratio: 2.31 GF Score: 36/100

Cullinan Oncology Inc at Needham Healthcare Conference (Virtual) Transcript

Apr 13, 2022 / 12:00PM GMT
Release Date Price: $11.59 (+3.48%)
Gil Blum
Needham & Company, LLC - Analyst

Good morning, and welcome to day 3 of the annual Needham & Company healthcare conference. My name is Gil Blum, and I am a senior biotech analyst here at Needham & Company, covering immuno-oncology and gene therapy subsectors. It is my pleasure to have with me this morning Jeff Trigilio, Chief Financial Officer for Cullinan Oncology. (Conference Instructions)

And with that, Jeff, you have the floor.

Jeff Trigilio
Cullinan Oncology, Inc. - CFO

Thanks, Gil, and thanks for the Needham organization for the support. Excited to talk about Cullinan today. Before I jump in, just a quick note that we'll be making forward-looking statements. Obviously, there's risk with these statements and uncertainty as to what will transpire. We would refer you to the 10-K and 10-Q filings in the SEC website to learn more about the risks of investing in our securities.

So let me start off on slide 3 by giving a couple of highlights on Cullinan. First and foremost is we are one of the broadest and deepest

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot